Literature DB >> 17526009

Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus.

Leland J Yee1, Yong-Ming Tang, David E Kleiner, Dai Wang, KyungAh Im, Abdus Wahed, Xiaomei Tong, Shannon Rhodes, Xiaowen Su, R Margaret Whelan, Robert J Fontana, Marc G Ghany, Brian Borg, T Jake Liang, Huiying Yang.   

Abstract

UNLABELLED: Candidate genes, including myxovirus resistance-1 (Mx1), protein kinase (PKR), transforming growth factor-beta1 (TGF-beta), interleukin-10 (IL-10), and interferon-gamma (IFN-gamma), were evaluated for associations with liver fibrosis in 374 treatment-naive patients with genotype-1 chronic HCV infection [194 Caucasian Americans (CAs) and 180 African Americans (AAs)], using a genetic haplotype approach. Among the 18 haplotypes that occurred with a frequency >or=5% in the cohort overall, the Mx1-(-123C)-(+6886A)-(+19820G(379V))-(+38645T) (abbreviated Mx1-CAGT), and PKR-(+110T)-(+7949G)-(+13846A)-(+22937T)-(+40342T) (abbreviated PKR-TGATT) haplotypes were independently associated with less severe hepatic fibrosis (Ishak >or= 3 versus <3). These associations persisted after adjustment for potential confounders such as alcohol use, sex, age (which is strongly correlated with the estimated duration of HCV infection [Spearman's correlation coefficient (r(s)) = 0.6)], and race (for Mx1-CAGT: OR = 0.33; 95% CI: 0.16-0.68; P = 0.0027; and for PKR-TGATT: OR = 0.56; 95% CI: 0.32-0.98; P = 0.0405). Population structure was evaluated using the structured association method using data from 161 ancestry-informative markers and did not affect our findings. We used an independent cohort of 34 AA and 160 CA in an attempt to validate our findings, although notable differences were found in the characteristics of the two patient groups. Although we observed a similar protective trend for the Mx1-CAGT haplotype in the validation set, the association was not statistically significant.
CONCLUSION: In addition to other factors, polymorphisms in cytokine genes may play a role in the progression of HCV-related fibrosis; however, further studies are needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17526009     DOI: 10.1002/hep.21636

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

1.  Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C.

Authors:  Varun Saxena; Jennifer C Lai; Jacqueline G O'Leary; Elizabeth C Verna; Robert S Brown; R Todd Stravitz; James F Trotter; Kartik Krishnan; Norah A Terrault
Journal:  Liver Transpl       Date:  2012-05       Impact factor: 5.799

2.  Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C.

Authors:  Xiaowen Su; Leland J Yee; KyungAh Im; Shannon L Rhodes; YongMing Tang; Xiaomei Tong; Charles Howell; Darmendra Ramcharran; Hugo R Rosen; Milton W Taylor; T Jake Liang; Huiying Yang
Journal:  J Hepatol       Date:  2008-05-20       Impact factor: 25.083

3.  Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C.

Authors:  Leland J Yee; KyungAh Im; Abdus S Wahed; Teodorica Bugawan; Jia Li; Shannon L Rhodes; Henry Erlich; Hugo R Rosen; T Jake Liang; Huiying Yang
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

4.  Host genetics, steatosis and insulin resistance among African Americans and Caucasian Americans with hepatitis C virus genotype-1 infection.

Authors:  A Danielle Iuliano; Eleanor Feingold; Abdus S Wahed; David E Kleiner; Steven H Belle; Hari S Conjeevaram; Joseph Zmuda; T Jake Liang; Leland J Yee
Journal:  Intervirology       Date:  2009-04-25       Impact factor: 1.763

5.  Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection.

Authors:  S L Rhodes; H Erlich; K A Im; J Wang; J Li; T Bugawan; L Jeffers; X Tong; X Su; H R Rosen; L J Yee; T J Liang; H Yang
Journal:  Genes Immun       Date:  2008-04-17       Impact factor: 2.676

6.  Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection.

Authors:  L J Yee; K Im; B Borg; H Yang; T J Liang
Journal:  Genes Immun       Date:  2009-04-23       Impact factor: 2.676

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.